ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1152

Interleukin-37 As an Independent Disease Activity Marker of Adult-Onset Still’s Disease

Seoung Wan Nam1, SuMan Kang2, Hyoungyoung Kim3, Ga-Young Ahn4, Min Jung Kim3 and Dae-Hyun Yoo1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 3Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 4Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: adult-onset Still's disease and interleukins (IL), Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Diagnosis and accurate measurement of disease activity in adult-onset Still¡¯s disease (AOSD) are still challenging due to its heterogeneous clinical manifestations and the lack of serological markers. A few serological markers, such as ferritin, C-reactive protein (CRP), interleukin (IL)-18 have been suggested but their clinical role is limited. IL-37 is a novel anti-inflammatory cytokine belonging to IL-1 cytokine family. However, there has been no study on the role of IL-37 in AOSD patients.

Objectives: We aimed to investigate the role of IL-37 as a disease activity marker of patients with AOSD.

Methods: A total of 51 patients meeting the Yamaguchi criteria were recruited at a single university hospital. Patients¡¯ clinical data and additional laboratory study including serum IL-18 and IL-37 were acquired both at the definite disease flare status (defined as modified Pouchot score 4 or more) and at the definite disease remission status (with modified Pouchot score 2 or less without significant clinical symptoms for more than a month). AOSD disease activity markers were compared between flare and remission status by Wilcoxon signed rank test and their correlation were evaluated by Spearman¡¯s correlation test.

Results: The mean age of study population was 48.8 ¡¾ 2.0. The mean interval between flare and remission was 7.2 ¡¾ 0.6 months. There were significantly higher levels of modified Pouchot score, serum ferritin, CRP, IL-18 and IL-37 level in flare status compared to remission (p<0.01) supporting their roles as disease activity markers. IL-37 level positively correlated with other AOSD disease activity markers including modified Pouchot score, CRP, and ferritin at flare status. The sensitivity and specificity of IL-37 for the disease flare status were 80 % and 82 %, respectively, at a cut-off value of 82.1 pg/mL. The AUC for IL-37 was 0.85 (95% confidence interval of 0.78-0.93). IL-18 level showed highest correlation with ferritin level at flare status (Spearman¡¯s Rho = 0.632, p<0.01). In contrast, IL-37 level had highest correlation with CRP level at flare status (Spearman¡¯s Rho = 0.574, p<0.01). And, there was no significant correlation between IL-18 and IL-37 levels (p=0.13). These differences in the presentation of interactive relationship between cytokines and other disease activity markers suggest the different role of IL-37 from that of IL-18 in activated AOSD status.

Conclusion: IL-37 can be used as an efficient disease activity marker in AOSD patients. And, it has a distinctive role as disease activity marker and inflammatory modulator in AOSD patients.

 



Disclosure: S. W. Nam, None; S. Kang, None; H. Kim, None; G. Y. Ahn, None; M. J. Kim, None; D. H. Yoo, Celltrion Inc., 5.

To cite this abstract in AMA style:

Nam SW, Kang S, Kim H, Ahn GY, Kim MJ, Yoo DH. Interleukin-37 As an Independent Disease Activity Marker of Adult-Onset Still’s Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/interleukin-37-as-an-independent-disease-activity-marker-of-adult-onset-stills-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-37-as-an-independent-disease-activity-marker-of-adult-onset-stills-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology